

Eritrea

Population 2015

5.2 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.6 (0.28–1.1)	12 (5.3–20)
Mortality (HIV+TB only)	0.053 (0.018–0.11)	1 (0.34–2)
Incidence (includes HIV+TB)	3.4 (1.6–5.9)	65 (30–113)
Incidence (HIV+TB only)	0.18 (0.085–0.32)	3.5 (1.6–6.1)
Incidence (MDR/RR-TB)**	0.14 (0–0.29)	2.7 (0–5.5)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.3 (0.12–0.49)	1.3 (0.31–2.2)	1.6 (0.42–2.7)
Males	0.33 (0.19–0.47)	1.5 (0.79–2.2)	1.8 (0.98–2.7)
Total	0.63 (0.4–0.86)	2.8 (1.6–4)	3.4 (1.6–5.9)

TB case notifications, 2015	
Total cases notified	2 094
Total new and relapse	2 060
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	65%
- % bacteriologically confirmed among pulmonary	59%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	61% (35–130)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.22 (0.08–0.48)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	111	5%
- on antiretroviral therapy	103	93%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			63 (9–120)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	21% (2.2–39)	
% notified tested for rifampicin resistance		84%	135
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 32, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 32, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	91%	2 389
Previously treated cases, excluding relapse, registered in 2014	88%	34
HIV-positive TB cases, all types, registered in 2014	83%	128
MDR/RR-TB cases started on second-line treatment in 2013	83%	6
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	21% (19–23)

TB financing, 2016	
National TB budget (US\$ millions)	4.2
Funding source: <1% domestic, 43% international, 57% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse


— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB

Total budget (US\$ millions)



— Unfunded

— Funded internationally

— Funded domestically